14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 61 days ( 0 % )
Last Price $0.0085 0 %
High/ Low $0.0085 - $0.0085 0%
Chg 7 Days N/A $0.0085 $0.0085
Chg 30 Days N/A $0.0085 $0.0085
Chg 12 mos -99.61 % $2.20 $0.0085
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos -40.39 % Width: 186.84 %
Pred. range - 3 mos N/A - N/A -100.00 % - -100.00 %
Pred. range - 12 mos N/A - $0.795 -100.00 % - 9,254.80 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 3 mos Sell Nov 30, -1 - N/A days
Short MA avg 12 mos Sell Apr 10, 2023 - 64 days
Long MA avg 12 mos Sell Apr 10, 2023 - 64 days
Short/Long MA avg 12 mos Sell Apr 10, 2023 - 64 days
Pivot Short Buy Jul 10, 2023 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Otonomy

Otonomy Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the trea... OTIC Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT